Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.

Ronald de Wit,Thomas Powles,Daniel Castellano,Andrea Necchi,Jae-Lyun Lee,Michiel S. van der Heijden,Nobuaki Matsubara,Aristotelis Bamias,Aude Flechon,Cora N. Sternberg,Alexandra Drakaki,Evan Y. Yu,Oday Hamid,Annamaria Zimmermann,Ling Gao,Amanda Long,Richard A. Walgren,Katherine M. Bell-McGuinn,Daniel Peter Petrylak

Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.

2018

Ronald de Wit
Thomas Powles
Daniel Castellano
Andrea Necchi
Jae-Lyun Lee
Michiel S. van der Heijden
Nobuaki Matsubara
Aristotelis Bamias
Aude Flechon
Cora N. Sternberg
Alexandra Drakaki
Evan Y. Yu
Oday Hamid
Annamaria Zimmermann
Ling Gao
Amanda Long
Richard A. Walgren
Katherine M. Bell-McGuinn
Daniel Peter Petrylak

4526Background: RAM+DOC improved PFS & had acceptable safety in UC (Petrylak, et al Lancet, 2017). RAM ER relationships are reported. Methods: Pts received RAM (10 mg/kg) + DOC (75 mg/m2) or placeb...

Keywords:

Carcinoma
Ramucirumab
Platinum
Physical therapy
Cancer research
Medicine
Docetaxel
Urology
urothelial carcinoma
exposure response
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations